Long Focus Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Long Focus Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,098,000	Closed	-$393K	–	105
2024 Q2	$393K	Hold	1,098,000	–	–	0.02%	92
2024 Q1	$736K	Sell	1,098,000 -274,000	-20%	-$199K	0.04%	86
2023 Q4	$745K	Hold	1,372,000	–	–	0.02%	94
2023 Q3	$823K	Buy	1,372,000 +100,000	+8%	+$107K	0.03%	88
2023 Q2	$1.65M	Buy	1,272,000 +200,000	+19%	+$273K	0.08%	71
2023 Q1	$1.89M	Hold	1,072,000	–	–	0.11%	74
2022 Q4	$3.37M	Buy	1,072,000 +542,000	+102%	+$2.1M	0.23%	57
2022 Q3	$2.6M	Hold	530,000	–	–	0.25%	56
2022 Q2	$2.19M	Buy	530,000 +190,000	+56%	+$822K	0.23%	64
2022 Q1	$1.98M	Buy	340,000 +95,000	+39%	+$565K	0.25%	61
2021 Q4	$1.84M	Buy	+245,000	New	+$2.13M	0.24%	56

Other funds holding SGMO

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Long Focus Capital Management's SGMO Position: Q3 2024 in Review

Long Focus Capital Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2024, closing a stake of 1,098,000 shares — an estimated $393K sold.

Long Focus Capital Management first reported a position in SGMO in Q4 2021 and held it in 11 quarters. The position peaked at $3.37M in Q4 2022. 103 funds tracked by Wall St. Rank hold SGMO as of Q3 2024.

Long Focus Capital Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2024 after selling out during the quarter.
Long Focus Capital Management sold 1,098,000 SANGAMO THERAPEUTICS INC shares in Q3 2024, an estimated $393K.
Long Focus Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q4 2021 and held it in 11 quarters.
Long Focus Capital Management's SANGAMO THERAPEUTICS INC position peaked at $3.37M in Q4 2022.
103 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2024.

Based on Long Focus Capital Management's 13F filing for Q3 2024, filed 13 Nov 2024.